New Two-Pronged attack on advanced cancers enters human testing
NCT ID NCT06848699
Summary
This study is testing a new combination of two immunotherapy drugs, HLX43 and serplulimab, for people with advanced solid tumors or a specific type of lung cancer. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. It will enroll about 105 adults whose cancer has progressed despite other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Provincial Cancer Hospital
RECRUITINGHunan, Changsha, 410031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Second Affiliated Hospital of Army Medical University, PLA
RECRUITINGChongqing, 400000, China
Contact
-
Shandong Cancer Hospital
RECRUITINGJinan, Shangdong, China
Conditions
Explore the condition pages connected to this study.